Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 10/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18238338 | 0.79 | PDE3B (0.43) | HTR3AKCNH2GAAALDH1A1 | |
| SCHEMBL778983 | 0.77 | HTT (0.50) | HTTHSD17B10PSMB8KDM4EGAA | |
| SCHEMBL24330409 | 0.73 | HTT (0.50) | HTTHSD17B10PSMB8KDM4EGAA | |
| SCHEMBL22530441 | 0.73 | HSD17B10 (0.50) | HTTHSD17B10PSMB8KDM4EGAA | |
| SCHEMBL22530235 | 0.73 | HTT (0.50) | HTTHSD17B10PSMB8KDM4EGAA | |
| SCHEMBL24506821 | 0.64 | TYMS (0.43) | HTR3AGAAALDH1A1MEN1MAPT | |
| SCHEMBL14871075 | 0.63 | HTR3A (0.46) | HTTHSD17B10HTR3AKCNH2KDM4E | |
| SCHEMBL13486491 | 0.62 | HTR3A (0.44) | HTTHSD17B10HTR3AKCNH2KDM4E | |
| SCHEMBL11465933 | 0.62 | PDE3B (0.41) | — | |
| SCHEMBL13377818 | 0.62 | ALDH1A1 (0.38) | HSD17B10KDM4EGAAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814888-A1 | AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Incorporated (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060173179-A1 | Azabenzoxazoles for the treatment of CNS disorders | PFIZER INC | 2006-08-03 | — | — | US | disclosed |
| WO-2006051394-A1 | AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173179-A1 | Azabenzoxazoles for the treatment of CNS disorders | CHRNA7, CHRNA5, CHRNA10 | HTT 4132/4885HSD17B10 1394/4885HTR3A 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.